EMCURE - Investment Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Investment Rating: 3.8

💊 Fundamental Analysis: Emcure Pharmaceuticals (EMCURE)

Emcure is a mid-cap pharmaceutical company with strong earnings momentum and improving profitability. While its fundamentals are solid, valuation and institutional sentiment present caution flags for long-term investors.

Metric Value Implication

P/E Ratio 38.8 Slightly above industry PE (34.0) — mildly overvalued

PEG Ratio 30.3 Very high — suggests valuation exceeds earnings growth

ROCE / ROE 20.8% / 18.6% Good — efficient use of capital

Dividend Yield 0.00% No passive income — growth-focused strategy

Debt-to-Equity 0.23 Manageable — not over-leveraged

EPS ₹36.0 Strong earnings base

Qtr Profit Var +69.5% Excellent — strong earnings momentum

FII/DII Holding Change -0.20% / -0.60% Negative — institutional investors reducing exposure

📉 Technical Analysis

Current Price: ₹1,409

DMA 50 / DMA 200: ₹1,303 / ₹1,251 → Bullish trend intact

RSI: 66.0 → Approaching overbought zone

MACD: +34.0 → Strong bullish momentum

Volume: Below average — rally lacks strong participation

💰 Ideal Entry Price Zone

₹1,250–₹1,320

This range aligns with DMA support and offers better valuation comfort

Avoid fresh entry above ₹1,450 unless earnings growth sustains and PEG normalizes

📈 Long-Term Investment Outlook

Strengths

Strong quarterly profit growth (+69.5%)

Healthy ROCE and ROE — efficient capital deployment

EPS of ₹36 — solid earnings base

Bullish technical setup — price above key moving averages

Risks

PEG > 30 — valuation far exceeds growth expectations

No dividend — purely growth play

FII/DII trimming — lack of institutional conviction

RSI near 70 — short-term correction possible

Emcure is a growth-oriented pharma stock with strong earnings momentum and decent capital efficiency. However, its valuation is stretched, and institutional sentiment is weak. Suitable for long-term investors who are comfortable with volatility and growth-centric plays.

🏁 Exit Strategy / Holding Period

If you already hold EMCURE

Holding Period: 3–5 years — allow time for earnings to catch up with valuation

Exit Strategy

Consider partial exit near ₹1,550–₹1,580 if PEG remains elevated and RSI crosses 70

Reassess if ROCE drops below 15% or profit growth slows

Hold if earnings growth continues and valuation moderates toward PEG < 2

Would you like a peer comparison with companies like Cipla, Alkem, or Torrent Pharma to explore alternatives with better valuation-to-growth balance?

Edit in a page